Obsessive-Compulsive Disorder (OCD) therapy encompasses psychotherapeutic and pharmacological interventions designed to dismantle the cycle of intrusive cognitions (obsessions) and ritualistic behaviours (compulsions). First-line treatment is Exposure and Response Prevention (ERP), a specialised CBT wherein patients voluntarily confront fear-provoking stimuli while refraining from neutralising rituals. ERP demonstrates robust efficacy, with meta-analyses revealing large effect sizes (Hedges’ g = 0.97) and approximately 50-70% reduction in symptom severity. Complementing psychotherapy, Selective Serotonin Reuptake Inhibitors (SSRIs) (fluoxetine, sertraline, escitalopram) represent the cornerstone of biological intervention, preferred over clomipramine due to superior side effect profiles.
For the 20% of patients who have partial or non-response to ERP, third-wave cognitive therapies offer promising alternatives. Acceptance and Commitment Therapy (ACT) targets psychological inflexibility through cognitive defusion—separating thought content from behavioural impact. An 8-week group ACT intervention demonstrated significant reductions in obsessive beliefs, accounting for 26% of the variance in symptom measures. Metacognitive Therapy (MCT) modifies dysfunctional metacognitive beliefs by teaching detached mindfulness to observe intrusions as transient mental events rather than as threats. Inference-based CBT (I-CBT) targets inferential confusion—distrusting senses in favour of hypothetical possibilities.
Clinical efficacy is substantiated by rigorous evidence. A meta-analysis of 30 studies (1,793 participants) confirmed ERP’s superiority over placebo. Comparative trials indicate that ERP and Emotion-Focused Therapy (EFT) both significantly reduce experiential avoidance and intolerance of uncertainty (p < 0.01). For refractory cases, augmentation with low-dose atypical antipsychotics (e.g., risperidone) may be considered. Emerging innovations include telehealth delivery of ERP, mixed reality exposure, and investigational agents (psilocybin, ketamine), though these remain experimental.
OCD therapy has evolved from a monolithic to a pluralistic discipline, offering evidence-based options honouring the disorder’s heterogeneity. Whether through ERP’s systematic desensitisation, ACT’s acceptance-oriented stance, MCT’s metacognitive recalibration, or SSRIs’ serotonergic modulation, the shared goal remains liberation from the tyrannical grip of doubt. With approximately 60-80% of patients achieving significant symptom reduction with specialised treatment, the prognosis is favourable, underscoring the critical importance of accurate diagnosis and access to proficient, disorder-specific care.
